Fosaprepitant dimeglumine and Musculoskeletal pain - a phase IV clinical study of FDA data

Summary:

Musculoskeletal pain is reported as a side effect among people who take Fosaprepitant dimeglumine (fosaprepitant dimeglumine), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Remicade, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Musculoskeletal pain when taking Fosaprepitant dimeglumine. It is created by eHealthMe based on reports of 1,528 people who have side effects when taking Fosaprepitant dimeglumine from the FDA, and is updated regularly.

What is Fosaprepitant dimeglumine?

Fosaprepitant dimeglumine has active ingredients of fosaprepitant dimeglumine. eHealthMe is studying from 1,528 Fosaprepitant dimeglumine users. Check the latest studies of Fosaprepitant dimeglumine.

What is Musculoskeletal pain?

Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves) is found to be associated with 1,878 drugs and 1,825 conditions by eHealthMe. Check the latest studies of Musculoskeletal pain.

On Jul, 18, 2026

1,528 people reported to have side effects when taking Fosaprepitant dimeglumine.
Among them, 20 people (1.31%) have Musculoskeletal pain.

Could Fosaprepitant dimeglumine cause Musculoskeletal pain?

Among these 20 people:

How long have people been on Fosaprepitant dimeglumine when they have Musculoskeletal pain? *

What is the gender of people who have Musculoskeletal pain when taking Fosaprepitant dimeglumine? *

female: 83.33 %
male: 16.67 %

What is the age of people who have Musculoskeletal pain when taking Fosaprepitant dimeglumine? *

What are other drugs people take besides Fosaprepitant dimeglumine? *

Simponi: 12 people, 60.00%
Remicade: 12 people, 60.00%
Acetaminophen: 10 people, 50.00%
Hydrocortisone Acetate: 10 people, 50.00%
Humira: 10 people, 50.00%
Orencia: 10 people, 50.00%
Fosamax: 10 people, 50.00%
Folic Acid: 10 people, 50.00%
Erelzi: 10 people, 50.00%
Enbrel: 10 people, 50.00%

What are other side effects people have besides Musculoskeletal pain? *

Nausea (feeling of having an urge to vomit): 15 people, 75.00%
Infusion Related Reaction: 15 people, 75.00%
Nausea And Vomiting: 14 people, 70.00%
Dyspnea (difficult or laboured breathing): 14 people, 70.00%
Abdominal Discomfort: 13 people, 65.00%
Stomatitis (inflammation of mucous membrane of mouth): 13 people, 65.00%
Rashes (redness): 13 people, 65.00%
Fever: 13 people, 65.00%
Pain: 13 people, 65.00%
Hair Loss: 13 people, 65.00%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 12 people, 60.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 9 people, 45.00%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 6 people, 30.00%
Psoriasis (immune-mediated disease that affects the skin): 6 people, 30.00%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 3 people, 15.00%
High Blood Pressure: 3 people, 15.00%
Joint Pain: 3 people, 15.00%
Muscle Aches (muscle pain): 2 people, 10.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 10.00%
Diabetes: 2 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Fosaprepitant dimeglumine and have Musculoskeletal pain?

- Check whether Musculoskeletal pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fosaprepitant dimeglumine:

Fosaprepitant dimeglumine (1,528 reports)

Browse all side effects of Fosaprepitant dimeglumine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Musculoskeletal pain:

Musculoskeletal pain (1,878 drugs)

Browse all the conditions that are associated with Musculoskeletal pain:

Musculoskeletal pain (1,825 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fosaprepitant dimeglumine (the active ingredients of Fosaprepitant dimeglumine) and Fosaprepitant dimeglumine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.